At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

Currently, the only FDA-approved OTC weight loss drug is Alli, which uses a 60-milligram dose of orlistat versus 120 ...

The weight loss jab Mounjaro will soon be made available to nearly a quarter of a million NHS patients, according to ...

A daily diet pill has shown promising results in early trials, with participants losing an average of 13% of their body weight in 12 weeks compared to 6% in those taking the Wegovy injection.

A new weight loss pill developed by the maker of Ozempic and ... a GLP-1 receptor agonist that is used to treat diabetes and obesity. The phase one trial of amycretin, led by Novo Nordisk ...

The future of oral weight loss medication looks bright. Drug manufacturer Novo Nordisk announced a new experimental ...

The maker of injectable weight loss drugs including ... for the Study of Diabetes meeting in Madrid. In this undated stock photo, a hand is shown holding pills. STOCK PHOTO/Getty Images The ...

Eli Lilly explores expanding its weight-loss drugs, Mounjaro and Zepbound, to individuals with a BMI below 27 to prevent ...

These pills are specifically designed to assist people with diabetes in managing their weight, as weight control is a crucial aspect of diabetes management. The gummies hasten weight loss by ...

Novo Nordisk was one of 10 companies with diabetes and weight loss drugs ... GPCR shares rose 8% in June after the company's GLP-1 weight loss pill glowed in mid-stage clinical trials.

The Danish drugmaker reported last year that a late-stage study in people who don’t have diabetes showed that the daily pill led to an average weight loss of 15% over 68 weeks, a similar result ...